SMARCA4 and non-small cell lung carcinoma: In the case, we reported, based on the 18F-FDG PET/CT findings (Figure 1), the patient’s pathological and immunohistochemical findings confirmed SMARCA4-deficient NSCLC (Figure 2), and clinical stage was T2N3M1, stage IVB.